Abiopharma

🔍 Wilks Dan H. (Executive)

Company: ProFrac Holding Corp. (ACDC)

Report Date: 2026-08-21

Detailed Transactions and Holdings:

• Acquired 212,650 shares of Class A common stock, par value $0.01 per share at $4.7445 per share (Direct)
  Date: 2026-08-21 | Code: P | equity_swap_involved: 0 | shares_owned_after: 87,712,845.00 | transaction_form_type: 4 | Footnotes: F1, F2, F1
• Acquired 363,757 shares of Class A common stock, par value $0.01 per share at $4.7026 per share (Direct)
  Date: 2026-08-24 | Code: P | equity_swap_involved: 0 | shares_owned_after: 88,076,602.00 | transaction_form_type: 4 | Footnotes: F1, F4, F1
• Acquired 30,820 shares of Class A common stock, par value $0.01 per share at $4.8062 per share (Direct)
  Date: 2026-08-25 | Code: P | equity_swap_involved: 0 | shares_owned_after: 88,107,422.00 | transaction_form_type: 4 | Footnotes: F1, F5, F1

Footnotes:

• F1: Reflects shares of the Issuer's Class A common stock acquired in the open market directly by THRC Holdings LP. The general partner of THRC Holdings is THRC Management LLC, a Texas limited liability company. Dan Wilks is the sole member of THRC Management LLC and may be deemed to exercise voting and investment power over the shares of the Issuer's Class A common stock directly owned by THRC Holdings LP, and therefore may be deemed to beneficially own such shares.
• F2: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.65 to $4.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• F3: Each Reporting Person disclaims beneficial ownership of all equity securities reported herein except to the extent of its respective pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any such Reporting Person is the beneficial owner of any equity securities covered by this Form 4.
• F4: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.63 to $4.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• F5: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.74 to $4.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.